lp

Lp-PLA2-IN-3 is a potent, orally bioactive lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor, effectively inhibiting recombinant human [Lp-PLA2] with an IC50 value of 14 nM.

LP-922761 is a potent, selective, and orally active AAK1 inhibitor with inhibitory effects on BMP-2 induced protein kinase (BIKE).

LP-471756 is a specific antagonist of GPR139 and inhibits LP-360924-stimulated cAMP production (IC50 = 640 nM).

Lp-PLA2-IN-2 is a selective and potent lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor, with an IC50 of 120 nM for recombinant human Lp-PLA2.

LP-533401 is an inhibitor of Tryptophan hydroxylase 1. It is used for regulates serotonin production in the gut.

LP-533401 hydrochloride is a peripheral Tph inhibitor that cannot cross the blood-brain barrier that inhibits 5-hydroxytryptamine synthesis and can be used to study periodontal disease and hepatic steatosis.

LP-935509 is a selective, brain-permeable, small molecule competitive inhibitor of articulin-2-associated kinase 1 (AAK1) with an IC50 of 3.3 nM and a Ki of 0.9 nM. LP-935509 is a potent inhibitor of BIKE (IC50 of 14 nM) and a moderate inhibitor of GAK (IC50 of 320±40 nM).

Lp-PLA2-IN-1 (Lp-PLA2 inhibitor 1) suppresses Lp-PLA2 activity processes for their preparation. Lp-PLA2-IN-1 (Lp-PLA2 inhibitor 1) also inhibits to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example, atherosclerosis, Alzheimer's disease.

LPA2 antagonist 3 (compound 15) serves as an Lp(a) antagonist. Lp(a) is a pathogenic risk factor for atherosclerotic cardiovascular disease (ASCVD).

Lp(a)-IN-5 (Compound A) is an orally active inhibitor of lipoprotein (a) [Lp(a)]. It effectively inhibits the assembly of Apo(a) and ApoB proteins, with an IC50 value of 0.41 nM. Lp(a)-IN-5 shows potential for research into diseases associated with elevated plasma Lp(a) levels, such as cardiovascular diseases.

Lp(a)-IN-6 (Compound 6) is an inhibitor of lipoprotein (a) [Lp(a)], exhibiting an IC50 value of less than 0.314 nM. It is utilized in research related to cardiovascular diseases (CVD).

Lp(a)-IN-7 (example 1) is an inhibitor of lipoprotein (a) [Lp(a)] formation, exhibiting an IC50 of 2.51 nM in media containing apolipoprotein B (apoB) and apolipoprotein (a). This compound is applicable in cardiovascular disease research.

ligand of the 5-HT7 receptor

LP 130 is an inhibitor of retroviral protease.

LP-403812 is a potent inhibitor of the proline transporter.

LP-20 is a bioactive chemical.

LP-360924 is a bioactive chemical.

LP 12 hydrochloride is a selective 5-HT7 receptor agonist (Ki=0.13 nM). LP 12 hydrochloride is selective for 5-HT7 over D2, 5-HT1A, and 5-HT2A receptors (Ki values of 224 nM, 60.9 nM, and >1000 nM, respectively).

LP-922056 is an inhibitor of Notum Pectinacetylesterase with EC50 values of 21 nM, 55 nM for human and mouse, respectively.

LP-184 (Compound 6), referred to as an acylfulvene analog, demonstrates the ability to inhibit tumor growth with noteworthy anti-cancer efficacy observed across multiple cell lines, including ovarian, colon, prostate, and pancreatic.

LP-211 is a brain penetrant selective agonist for a 5-HT7 receptor (Ki: 0.58 nM), and >300-fold selectivity over the 5-HT1A receptor.

LP-284 is a potent DNA alkylating agent that kills solid tumors and can be used in hematologic cancer studies with compromised DNA repair, such as mantle cell lymphoma (MCL) [1] [2].

LP-922761 hydrate is a selective, potent, orally active AAK1 inhibitor with IC50 values of 4.8 nM and 7.6 nM in enzyme and cellular assays, respectively. LP-922761 hydrate inhibits BMP-2 inducible protein kinase (BIKE) (IC50: 24 nM). 922761 hydrate has no significant effect on cellular GAK, opioids, adrenergic α2 or GABAa receptors.

Lp-PLA2-IN-11 is a potent inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2) with potential applications in diseases associated with Lp-PLA2 activity [e.g., atherosclerosis, Alzheimer's disease].